Osteoporosis
📧 Sign up to get email alerts when something new happens for Osteoporosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-04-26Clinical Trial Update: Comparative Efficacy, Safety, PK, and Immunogenicity Study [Phase 3]
Phase 3 clinical trial update evaluating comparative efficacy, safety, pharmacokinetics, and immunogenicity in postmenopausal osteoporosis; …
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Study on the Prevention and Treatment of GIOP With Eldecalcitol [Phase 4]
Phase 4 clinical trial update evaluating eldecalcitol for prevention and treatment of glucocorticoid-induced osteoporosis, with study popula…
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: Denosumab Sequential Therapy [Phase 4]
Phase 4 clinical trial update for denosumab sequential therapy in osteoporosis has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
Real-world effectiveness and cardiovascular safety study of abaloparatide in postmenopausal women has completed with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis [Phase 3]
Phase 3 trial evaluating TVB-009P for relief of postmenopausal osteoporosis has completed; results posted in 2024.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2024-04-12EMA Authorised: Eladynos (abaloparatide) — Theramex Ireland Limited
EMA has authorised Eladynos (abaloparatide) for osteoporosis, including postmenopausal osteoporosis, with Theramex Ireland Limited as the MA…
-
CLINICAL_TRIALS trial_result · 2024-04-11Clinical Trial Update: Effect of Pitavastatin on Bone [Phase 4]
Phase 4 trial exploring the effect of pitavastatin on bone health in patients with osteoporosis/osteopenia and hypercholesterolemia; study c…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Zoledronate Early to Hip Fracture Patients - Safe and Effective? [Phase 4]
Phase 4 clinical trial updating on early zoledronate use in hip fracture patients to assess safety and efficacy.
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: Effects of Exemestane on Bone Strength
A completed clinical trial assessing the effects of exemestane on bone strength in patients with osteoporosis and breast cancer; results pos…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury [Phase 4]
Phase 4 trial update on denosumab for secondary osteoporosis in spinal cord injury patients; the study is terminated.
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating denosumab for bone loss associated with donor stem cell transplant, completed with results posted in 2024.
-
FDA approval · 2024-03-05FDA Approved: PROLIA — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for PROLIA (denosumab) submitted by Amgen. The action indicates an expanded or updated indication fo…
-
FDA approval · 2024-03-05FDA Approved: WYOST — Original Application (Sandoz Inc)
FDA approved WYOST (denosumab) from Sandoz Inc under an original Biologics License Application.
-
CLINICAL_TRIALS trial_result · 2024-02-22Clinical Trial Update: Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients [Phase 4]
Phase 4 trial update evaluating alfacalcidol effects on muscle function in osteoporosis-related sarcopenia.
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial update on prevention of bone loss after pediatric hematopoietic cell transplantation.
-
FDA approval · 2024-01-19FDA Approved: PROLIA — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for Prolia (denosumab) from Amgen.
-
CLINICAL_TRIALS trial_result · 2024-01-19Clinical Trial Update: Utilizing Protein During Weight Loss to Impact Physical Function and Bone [NA]
A completed clinical trial investigating the role of a protein during weight loss and its impact on physical function and bone health.
-
FDA approval · 2024-01-08FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for risendronate sodium by Sun Pharmaceutical Industries, expanding or modifying its labeling un…
-
FDA approval · 2023-12-21FDA Approved: TYMLOS — Supplemental Application (Radius Health, Inc.)
FDA approved a supplemental application for TYMLOS (abaloparatide) submitted by Radius Health, Inc., updating the labeling for osteoporosis …
-
FDA approval · 2023-12-18FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Sun Pharmaceutical Industires Inc.)
The FDA approved a supplemental application for Risedronate Sodium submitted by Sun Pharmaceutical Industries Inc.
-
CLINICAL_TRIALS trial_result · 2023-12-08Clinical Trial Update: Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men [Phase 3]
Phase 3 trial comparing zoledronic acid plus Colaren to zoledronic acid with conventional treatment in men with secondary osteoporosis (HIV …
-
CLINICAL_TRIALS trial_result · 2023-12-04Clinical Trial Update: Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of PBK_L2201 in postmenopausal women with osteoporosis is ongoing.
-
CLINICAL_TRIALS trial_result · 2023-11-27Clinical Trial Update: Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis [Phase 2]
Phase 2 clinical trial investigating alendronate for osteoporosis in patients with rheumatoid arthritis has completed.
-
FDA approval · 2023-11-16FDA Approved: TERIPARATIDE — Supplemental Application (Alvogen, Inc.)
The FDA approved a supplemental application for teriparatide submitted by Alvogen, Inc.
-
FDA approval · 2023-11-16FDA Approved: TERIPARATIDE — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for generic teriparatide (Teriparatide) to treat osteoporosis.